CONSHOHOCKEN, Pa. & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--March 20, 2006--Neuromed Pharmaceuticals Ltd. and Merck & Co., Inc. announced today that they have signed a research collaboration and license agreement to research, develop and commercialize novel compounds for the treatment of pain and other neurological disorders, including Neuromed's lead compound, NMED-160, which is currently in Phase II development for the treatment of pain.
